News | Annuloplasty Rings | January 02, 2019

Boston Scientific Exercises Option to Acquire Millipede Inc.

Acquisition will expand structural heart portfolio to include transcatheter mitral annuloplasty repair system

Boston Scientific Exercises Option to Acquire Millipede Inc.

January 2, 2019 — Boston Scientific Corp. exercised its option to acquire the remaining shares of Millipede Inc, a privately-held company in Santa Rosa, Calif., upon its recent successful completion of a first-in-human clinical study. The acquisition will expand the Boston Scientific Structural Heart portfolio to include the Iris Transcatheter Annuloplasty Ring System, which is in development for the treatment of patients with severe mitral regurgitation (MR) who are not able to tolerate open-heart surgery.

Boston Scientific initially entered into an investment and acquisition option agreement with Millipede in January 2018. It purchased $90 million in existing and newly-issued Millipede shares, with the option to acquire the company's remaining shares for $325 million at closing, with a $125 million payment becoming available upon achievement of a commercial milestone.

The quickly expanding transcatheter mitral repair and replacement market is estimated to reach $1 billion by 2021, with the majority comprised of repair procedures.

The Iris system uses a complete annuloplasty ring, considered the gold-standard surgical approach, to reduce the size of a dilated mitral annulus. It is delivered via a transcatheter-transseptal delivery system, and can be used as a stand-alone device, or in combination with other technologies in patients with severe MR.

The IRIS Transcatheter Annuloplasty Ring System is an investigational device and not available for sale.

For more information: www.bostonscientific.com

Related Content

LivaNova Receives FDA Clearance for Memo 4D Semi-Rigid Mitral Annuloplasty Ring
Technology | Annuloplasty Rings | June 15, 2018
LivaNova PLC announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Memo 4D semi-rigid...
Second Micro Interventional Devices Annuloplasty System Successfully Implanted
News | Annuloplasty Rings | October 30, 2017
Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings | July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings | July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings | April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings | February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings | September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Overlay Init